Tamoxifen
Research News and Information

Saturday, November 21, 2009

EGFRvIII-induced estrogen-independence, tamoxifen-resistance phenotype correlates with PgR expression and modulation of apoptotic molecules in breast cancer.

30 Oct 2009 The tumor-specific, ligand-independent, constitutively active epidermal growth factor receptor (EGFR) variant, EGFRvIII, remains understudied in breast cancer. Here, we report that expression of EGFRvIII in the ErbB-2-overexpressing, ... Read more...

Gal4 turnover and transcription activation.

6 Oct 2009 Growing evidence supports the notion that proteasome-mediated destruction of transcriptional activators can be intimately coupled to their function. Recently, Nalley et al. challenged this view by reporting that the prototypical yeast activator Gal4 ... Read more...

Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen.

5 Oct 2009 CONTEXT: The growth inhibitory effect of tamoxifen, which is used for the treatment of hormone receptor-positive breast cancer, is mediated by its metabolites, 4-hydroxytamoxifen and endoxifen. The formation of active metabolites is catalyzed by the ... Read more...

Latest indexed articles for 'Tamoxifen'

These are the very latest articles for this heading:

• Genetic matters of CYP2D6 in breast cancer: copy number variations and nucleotide polymorphisms. 30 Oct 2009
• EGFRvIII-induced estrogen-independence, tamoxifen-resistance phenotype correlates with PgR expression and modulation of apoptotic molecules in breast cancer. 30 Oct 2009
• Gal4 turnover and transcription activation. 6 Oct 2009
• Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. 5 Oct 2009
• Tamoxifen, antidepressants, and CYP2D6: the conundrum continues. 29 Sep 2009
• Pharmacology, pharmacogenetics, and pharmacoepidemiology: three ps of individualized therapy. 29 Sep 2009
• American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. 29 Sep 2009
• Selective estrogen receptor modulators decrease reactive astrogliosis in the injured brain: effects of aging and prolonged depletion of ovarian hormones. 22 Sep 2009
• Effects of tamoxifen and raloxifene on memory and other cognitive abilities: cognition in the study of tamoxifen and raloxifene. 19 Sep 2009
• TMEM25, REPS2 and Meis 1: favourable prognostic and predictive biomarkers for breast cancer. 19 Sep 2009
• Management of primary and advanced breast cancer in older unfit patients (medical treatment). 14 Sep 2009
• Improvement of the clinical applicability of the Genomic Grade Index through a qRT-PCR test performed on frozen and formalin-fixed paraffin-embedded tissues. 8 Sep 2009
• [Safety and compliance with UFT (tegafur and uracil) alone and in combination with hormone therapy in patients with breast cancer] 30 Aug 2009
• The antipsychotic drug chlorpromazine enhances the cytotoxic effect of tamoxifen in tamoxifen-sensitive and tamoxifen-resistant human breast cancer cells. 30 Aug 2009
• Comment on "Direct hematological toxicity and illegitimate chromosomal recombination caused by the systemic activation of CreER(T2)". 30 Aug 2009
• Estrogen receptor beta--an independent prognostic marker in estrogen receptor alpha and progesterone receptor-positive breast cancer? 30 Aug 2009
• Adjuvant hormonal therapy for breast cancer and risk of hormone receptor-specific subtypes of contralateral breast cancer. 23 Aug 2009
• Restoring endocrine response in breast cancer cells by inhibition of the sphingosine kinase-1 signaling pathway. 23 Aug 2009
• Antiestrogen-resistant subclones of MCF-7 human breast cancer cells are derived from a common monoclonal drug-resistant progenitor. 23 Aug 2009
• Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. 18 Aug 2009

See a longer list of these articles.

Technical information about 'Tamoxifen'

Definition: One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM.

Chemical name: Ethanamine, 2-(4-(1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethyl-, (Z)-

Registry Number: 10540-29-1

Descriptor UI: D013629

Alternative terms: Tamoxifen; ICI-47699; ICI 47699; ICI47699; Zitazonium; Soltamox; Savient brand of Tamoxifen Citrate; Tamoxifen Citrate; Citrate, Tamoxifen; Tomaxithen; ICI-46474; ICI 46474; ICI46474; ICI-46,474; ICI 46,474; ICI46,474; Nolvadex; Novaldex;

Allowable Qualifiers: administration & dosage; adverse effects; analogs & derivatives; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Pharmacological Action: Antineoplastic Agents, Hormonal; Selective Estrogen Receptor Modulators; Bone Density Conservation Agents; Estrogen Antagonists;

Tree Number: D02.455.426.559.389.150.700.900;

History Note: 78(75); was see under STILBENES 1975-77